I Have Mild Cognitive Impairment. Is It Alzheimer’s, and What Happens Next?

The diagnosis often follows a short screening test: a score a few points below the cutoff, then three words on a visit summary, mild cognitive impairment. Many people, and many of the adult children at the appointment, hear “early Alzheimer’s.” That is not what the words mean. This guide covers what MCI does and does not tell you, how often it progresses or improves, what the workup should look for, and what helps.

The Short Answer

Mild cognitive impairment (MCI) means memory or thinking has declined enough to show up on testing, while the person still manages daily life independently.¹ It names a pattern, not a disease. Alzheimer’s disease is a common cause, but vascular brain injury, Lewy body disease and treatable contributors such as medications, sleep apnea and depression can produce the same picture.¹

MCI does not always get worse. In a meta-analysis of 41 studies, about 5 percent of people with MCI in community studies and about 10 percent in specialist clinics progressed to dementia each year, and most had not developed dementia even after 10 years.² In population-based studies, about 1 in 4 people with MCI later tested normal again.³ The cause sets the outlook, which is why the next step is a workup to find it.

What Does a Diagnosis of Mild Cognitive Impairment Mean?

MCI has a specific definition. Under the National Institute on Aging and Alzheimer’s Association criteria, which the Alzheimer’s Association’s diagnostic guideline uses, all four of these must be true:¹

• A concern about change, raised by the person, someone who knows them well, or a clinician.
• Objective impairment in one or more areas of thinking, such as memory, attention, language or visual-spatial skills, on formal or bedside testing.
• Preserved independence in everyday activities.
• No dementia.

The psychiatric diagnostic manual’s equivalent, mild neurocognitive disorder, makes the third point concrete: complex tasks such as paying bills or managing medications are still done, though they may take more effort, reminders or workarounds.¹

A low score on a screening test such as the Montreal Cognitive Assessment (MoCA) raises the question; the full criteria, including a check of daily function, answer it.

Amnestic and non-amnestic MCI

Clinicians also sort MCI by which abilities are affected.⁴ In amnestic MCI, memory for new information is the main problem. In non-amnestic MCI, the difficulty lies mainly in attention, planning, language or visual-spatial skills.

The subtype is a clue to the cause. An amnestic pattern is usually due to Alzheimer’s disease, often mixed with vascular or Lewy body changes.¹ Prominent trouble with attention, planning and visual-spatial tasks, with memory and naming less affected, is more typical of Lewy body disease.⁵

Where MCI sits between normal aging and dementia

• Normal aging: slower recall and more tip-of-the-tongue moments, with test results in the expected range for age and full independence.
• Mild cognitive impairment: a measurable decline on testing, with independence preserved.¹
• Dementia: a decline that interferes with independence in everyday activities.¹

If you are still deciding whether recent changes are normal, start with how early Alzheimer’s differs from normal aging. This guide picks up after the diagnosis.

How Common Is Mild Cognitive Impairment?

MCI becomes more common with each decade of life. In the evidence review behind the American Academy of Neurology’s 2018 MCI guideline, prevalence was 6.7 percent at ages 60 to 64, 8.4 percent at 65 to 69, 10.1 percent at 70 to 74, 14.8 percent at 75 to 79, and 25.2 percent at 80 to 84.⁶ The AAN has since formally retired that guideline, but its review remains a useful summary of the data. MCI is common, and on its own it describes where someone stands today, not where they will be in five years.

Will Mild Cognitive Impairment Turn Into Alzheimer’s Dementia?

Some people with MCI progress to dementia, many stay stable for years, and a meaningful share improve. The rates depend on who is studied.

In the AAN review, 14.9 percent of people with MCI older than 65 had developed dementia after 2 years of follow-up.⁶ Across 41 cohort studies, the annual rate of progression to dementia was 9.6 percent in specialist clinics and 4.9 percent in community studies. Most people with MCI had not developed dementia even after 10 years.² People seen in memory clinics were usually referred because changes were already worrying, which likely explains part of the gap.

Can MCI go back to normal?

Yes, in a meaningful share of cases. A 2016 meta-analysis of 25 longitudinal studies found that 18 percent of people with MCI reverted to normal cognition overall: 8 percent in clinic-based studies and 25 percent in population-based studies.³ Some of this reflects a resolved cause, such as a stopped medication or treated depression; some reflects the limits of a single test on a single day.

Reversion is not an all-clear. The AAN review noted that people who revert remain at higher risk of progressing back to MCI or dementia, which is why follow-up continues even after a reassuring retest.⁶

What Causes Mild Cognitive Impairment?

MCI is a syndrome that several processes can produce, often more than one at a time. The Alzheimer’s Association’s 2025 diagnostic guideline names the main brain diseases (Alzheimer’s disease, vascular brain injury and Lewy body disease) alongside contributing conditions such as obstructive sleep apnea, medications that impair cognition, mood disorders and heavy alcohol use.¹ Its first-line workup includes blood tests, among them a complete blood count, a metabolic panel, thyroid-stimulating hormone (TSH) and vitamin B12, plus structural brain imaging, with MRI preferred and CT if MRI is not possible.¹

Finding Alzheimer’s disease does not end the search. Symptoms often come from a combination of causes,¹ and correcting the treatable ones can help even when the underlying disease remains.

How Do Biomarkers Change the Outlook in MCI?

Biomarker testing answers the question an MCI diagnosis alone cannot: is Alzheimer’s disease the cause? Under criteria revised by an Alzheimer’s Association workgroup in 2024, Alzheimer’s disease is defined biologically, and one abnormal “Core 1” biomarker is enough to establish it: amyloid PET, an approved spinal fluid test, or an accurate blood test, especially p-tau217.⁷

The result changes the forecast substantially. In a study pooling 13 cohorts of people with MCI, those whose amyloid and nerve-injury markers both pointed to Alzheimer’s disease had a 59 percent rate of progression to Alzheimer’s-type dementia within 3 years. When both markers were normal, the rate was 5 percent.¹⁴

A negative result redirects attention to vascular, Lewy body or reversible causes. A positive result makes Alzheimer’s disease a likely cause, and confirmed amyloid was required in the trials behind the approved anti-amyloid drugs.¹⁵ If you already have a blood result, see what a positive p-tau217 blood test means.

What Should the Workup After an MCI Diagnosis Include?

The Alzheimer’s Association guideline recommends a structured process that includes both the patient and a care partner.¹ Beyond the tests in the table above, that means:

• A history from you and from someone who knows you well, covering when changes began, how they have evolved, and what has become harder.
• A check of daily function: finances, medications, driving, appointments.
• Detailed cognitive testing, often neuropsychological testing, to define the subtype and set a baseline for comparison.
• Biomarker testing when the answer would change decisions.⁷
• APOE genotyping before any anti-amyloid treatment, because people with two copies of APOE4 have a higher rate of amyloid-related imaging abnormalities (ARIA), most often temporary brain swelling, on these drugs.¹⁵

A structured memory evaluation brings these steps together so the result is a cause, or a short list of causes, rather than a label.

What Treatments Help Mild Cognitive Impairment?

Exercise

Exercise has the clearest guideline support. The AAN review found that 6 months of exercise training is likely to improve cognitive measures in people with MCI, and its guideline recommended regular exercise, twice a week, as part of overall management.⁶ It also said clinicians may recommend cognitive training, a weaker recommendation.⁶

Cholinesterase inhibitors

Donepezil and related drugs are approved for Alzheimer’s dementia, not for MCI. The AAN found no high-quality evidence that any medication helps MCI. Its guideline said clinicians may choose not to offer cholinesterase inhibitors, and that if they do, they must first explain that this is an off-label use without supporting evidence.⁶

Anti-amyloid antibodies for MCI due to Alzheimer’s disease

When biomarkers confirm amyloid, there is now a disease-specific option. On July 6, 2023, the FDA granted lecanemab (Leqembi) traditional approval for patients with MCI or mild dementia due to Alzheimer’s disease, matching the trial population, which had confirmed amyloid.¹⁵ Donanemab (Kisunla) was approved on July 2, 2024, for the same early stages.¹⁶

The benefit is real but modest. In the lecanemab trial, scores on an 18-point dementia rating scale worsened by 1.21 points over 18 months with the drug and 1.66 points with placebo; brain swelling or fluid on MRI (ARIA-E) occurred in 12.6 percent of treated patients.⁸ In the donanemab trial, the same scale worsened by 1.72 points with the drug and 2.42 with placebo, and ARIA-E occurred in 24.0 percent.⁹ For eligibility, APOE4 and safety monitoring, see who qualifies for Leqembi and Kisunla.

Blood pressure control

In the SPRINT MIND trial, 9,361 adults aged 50 or older with high blood pressure, but without diabetes or prior stroke, were assigned a systolic target below 120 or below 140 mm Hg. The intensive target lowered new MCI from 18.3 to 14.6 cases per 1,000 person-years, about 19 percent fewer. The reduction in probable dementia (8.6 to 7.2 per 1,000 person-years) was not statistically significant.¹⁰ It was a prevention trial in people without dementia, not a treatment trial in MCI.

Multidomain lifestyle programs

Two large trials tested diet, exercise, cognitive training and vascular risk management together. In the Finnish FINGER trial, 1,260 adults aged 60 to 77 at elevated risk showed a small cognitive benefit over 2 years.¹⁷ In the U.S. POINTER trial, published in JAMA in August 2025, 2,111 adults aged 60 to 79 in a structured program improved slightly more on cognitive testing than those in a self-guided program, and the benefit appeared larger in people with lower cognition at the start.¹⁸ Neither trial enrolled people diagnosed with MCI, so the results are a guide, not proof, for this group.

What About Driving, Finances and Planning After an MCI Diagnosis?

The AAN guideline asked clinicians to discuss long-term planning with people who have MCI, including advance directives, driving safety, finances and estate planning.⁶ These conversations are easiest now, while decision-making is clearly intact.

• Legal documents: name a health care proxy and a financial power of attorney, and write down your wishes.
• Money: automatic bill payment and a trusted second person who can see account activity.
• Driving: MCI alone does not mean you must stop. Ask family for honest feedback, and consider a formal driving evaluation if there have been near misses or getting lost.

How Often Should Mild Cognitive Impairment Be Reassessed?

The AAN recommended serial assessments to monitor for change, without setting a fixed interval.⁶ Trajectory, whether stable, improving or declining, is the most informative thing to measure.

A reasonable rhythm is to repeat formal testing at about 12 months, sooner if family members notice a change, using the same tests so the comparison is fair.

Between visits, the signs worth reporting are new trouble with bills or medications, getting lost on familiar routes, repeating questions within a conversation, or a family member quietly taking over a task.

What Should You Do After an MCI Diagnosis?

1. Ask which type of MCI this is and what cause is suspected.
2. Complete the workup in the table above if it has not been done.
3. Correct what is correctable: medications, sleep apnea, mood, hearing, B12, thyroid and alcohol.
4. Decide about biomarker testing with a clinician who will act on either result.
5. Start regular exercise and get blood pressure to target now, whatever the cause.
6. Put the planning documents in place while it is straightforward to do so.
7. Book a reassessment, with the same tests, so change can be measured.

Common Questions

Is mild cognitive impairment the same as early Alzheimer’s disease?

No. MCI describes a level of impairment, not its cause. When biomarkers show Alzheimer’s changes, the diagnosis becomes MCI due to Alzheimer’s disease. Without them, Alzheimer’s is a possibility, not a conclusion.

Can mild cognitive impairment be reversed?

Sometimes. In population-based studies, about 25 percent of people with MCI later test normal, against about 8 percent in clinic-based studies.³ Improvement is most likely when a treatable contributor is found. People who revert still carry a higher risk of later decline, so follow-up continues.⁶

How quickly does MCI progress to dementia?

On average, about 5 to 10 percent of people with MCI progress to dementia each year, and most have not progressed after 10 years.² The individual outlook depends on the cause, and Alzheimer’s biomarkers sharpen it considerably.¹⁴

Is there a medication for mild cognitive impairment?

No drug treats MCI in general. Cholinesterase inhibitors such as donepezil are not approved for MCI, and the AAN found no good evidence that they help.⁶ For MCI due to Alzheimer’s disease with confirmed amyloid, lecanemab and donanemab are FDA-approved and modestly slow decline, with a risk of brain swelling (ARIA).^8,9

Should someone with MCI stop driving?

Not automatically. Driving safety should be discussed openly, with input from family, and a formal driving evaluation is reasonable after near misses or getting lost.

The Bottom Line

Mild cognitive impairment is a measurable change in thinking with independence intact. It is common, it has many causes, and it does not always progress. The useful response is neither alarm nor reassurance, but a workup: find the cause, fix what can be fixed, test for Alzheimer’s biology when the answer matters, and measure again over time.

---

Dr. Nadir Bilici, MD, DipIBLM, is a board-certified neurologist (ABPN) and Diplomate of the International Board of Lifestyle Medicine specializing in preventive neurology, Alzheimer’s prevention, and cognitive risk assessment. He sees patients by telehealth in the states where he is licensed, with in-person appointments available on a select basis.

References

1. Atri A, Dickerson BC, Clevenger C, et al. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for primary care. Alzheimers Dement. 2025;21(6):e14333. doi:10.1002/alz.14333
2. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia: meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252-265. doi:10.1111/j.1600-0447.2008.01326.x
3. Canevelli M, Grande G, Lacorte E, et al. Spontaneous reversion of mild cognitive impairment to normal cognition: a systematic review of literature and meta-analysis. J Am Med Dir Assoc. 2016;17(10):943-948. doi:10.1016/j.jamda.2016.06.020
4. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. doi:10.1111/j.1365-2796.2004.01388.x
5. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058
6. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-135. doi:10.1212/WNL.0000000000004826. Since retired by the AAN.
7. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024;20(8):5143-5169. doi:10.1002/alz.13859
8. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
9. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. doi:10.1001/jama.2023.13239
10. Williamson JD, Pajewski NM, Auchus AP, et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553-561. doi:10.1001/jama.2018.21442
11. Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677
12. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613-619. doi:10.1001/jama.2011.1115
13. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786-797. doi:10.1016/S0140-6736(23)01406-X
14. Vos SJB, Verhey F, Frölich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327-1338. doi:10.1093/brain/awv029
15. U.S. Food and Drug Administration. FDA converts novel Alzheimer's disease treatment to traditional approval. Press release. Published July 6, 2023. fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
16. Eli Lilly and Company. Lilly's Kisunla (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer's disease. Press release. Published July 2, 2024. investor.lilly.com
17. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263. doi:10.1016/S0140-6736(15)60461-5
18. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA. 2025;334(8):681-691. doi:10.1001/jama.2025.12923

Written and medically reviewed by Nadir Bilici, MD, DipIBLM. Published October 2026 · Medically reviewed on October 19, 2026. See our editorial policy.